NEW YORK, October 21, 2016 /PRNewswire/ --
Pre-market this morning Stock-callers.com looks at the performances ofthese four Biotech stocks: Raptor Pharmaceuticals Corporation (NASDAQ: RPTP), Amicus Therapeutics Inc. (NASDAQ: FOLD), Neuralstem Inc. (NASDAQ: CUR), and Macrocure Ltd (NASDAQ: MCUR) following a bearish trading session on Thursday,
On Thursday, shares in Novato, California headquartered Raptor Pharmaceuticals Corp. ended the session 0.28% higher at $9.00 with a total volume of 960,942 shares traded. Raptor Pharma's shares have gained 0.11% in the last one month, 48.51% in the previous three months and 60.43% in the past one year. The stock is trading 9.93% above its 50-day moving average and 58.54% above its 200-day moving average. Moreover, shares of the Company, which focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, have a Relative Strength Index (RSI) of 69.03. See our free and comprehensive research report on RPTP at:
Cranbury, New Jersey headquartered Amicus Therapeutics Inc.'s stock finished Thursday's session 5.87% higher at $7.57 with a total volume of 1.73 million shares traded. Over the past three months and the previous one year, shares of Amicus Therapeutics, which focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases, have gained 26.17% and 22.69%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 5.45% and 9.00%, respectively. Amicus Therapeutics' stock has an RSI of 53.99. FOLD free research report PDF is just a click away at:
Germantown, Maryland headquartered Neuralstem Inc.'s stock advanced 5.52%, to close the day at $0.30. The stock recorded a trading volume of 892,074 shares, which was above its three months average volume of 836,530 shares. Shares of Neuralstem, which focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds, have gained 14.62% in the last three months, it has declined 3.87% in the last one month and 75.97% in the past one year. The Company's shares are trading 4.19% above its 50-day moving average. Additionally, the stock has an RSI of 47.75. Sign up for your complimentary report on CUR at:
On Thursday, shares in Petach Tikva, Israel headquartered Macrocure Ltd recorded a trading volume of 63,756 shares. The stock ended the day 0.60% lower at $1.65. Macrocure's stock has gained 17.02% in the last one month and 7.14% in the previous three months. The Company is trading above its 50-day and 200-day moving averages by 7.56% and 32.36%, respectively. Furthermore, shares of Macrocure, which focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel, have an RSI of 55.28. Register for free on Stock-Callers.com and download the latest research report on MCUR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All